LUND, Sweden, Nov. 30, 2021 /PRNewswire/ -- Immunovia
AB (publ.) announced today that the Company's President and Chief
Executive Officer, Patrik Dahlen,
has informed the Board of Directors of his intention to step down,
for personal reasons. The search for a new CEO will start
immediately. Although Patrik Dahlen
will remain with the company for another six months to ensure an
orderly transition, the Board would like to take this opportunity
to express their gratitude already now for Patrik's many
contributions to the company.
Carl Borrebaeck, chairman of the Board of Directors, says:
"Immunovia's mission is to detect and prevent pancreatic cancer,
one of the deadliest cancer forms there is. Today, we stand
stronger than ever with our pioneering IMMray™ PanCan-d test.
Bringing us here has been a team effort, where Patrik has played a
crucial role and achieved regulatory approval and launched the
product, which is now available throughout the United States. We are now penetrating this
prioritized market according to our strategy and will continue to
do so with full focus. On behalf of the Board, I thank Patrik for
this outstanding effort."
Patrik Dahlen says:
"Immunovia is a fantastic company with an important mission and
solid strategy. It is a privilege to work with such knowledgeable
and committed colleagues. For personal reasons I will not be able
to be a part of the journey ahead, which I regret. But I am
confident that Immunovia will continue to successfully break new
ground in the future."
This is information that Immunovia is obliged to make public
pursuant to the EU Market Abuse Regulation. The information was
submitted for publication, through the agency of the contact person
set out above, at 08:20 CET on
November 30, 2021.
For more information, please contact:
Chairman of the Board, Immunovia: + 46 70 821 83 30
Patrik Dahlen, CEO, Immunovia: + 46
73 376 76 64
Immunovia AB is a diagnostic company that is developing and
commercializing highly accurate blood tests for the early detection
of cancer based on Immunovia's proprietary test platform
called IMMray™. Tests are based on antibody biomarker
microarray analysis using advanced machine-learning and
bioinformatics to single-out a set of relevant biomarkers that
indicate a certain disease. Thus, forming a unique "disease
The company was founded in 2007, based on cancer studies and
ground-breaking research in the Department of Immuntechnology at
Lund University and CREATE Health
Cancer Center, Sweden.
The first product, IMMray™ PanCan-d, is undergoing clinical
evaluation in some of the world's largest clinical studies for
high risk groups in pancreatic cancer, PanFAM-1, PanSYM-1 and
In 2017, Immunovia, Inc. was established in Marlborough, Massachusetts, USA. The IMMray™
PanCan-d test, the first blood-based test dedicated to the early
detection of pancreatic cancer on the market, is offered as a
laboratory developed test (LDT) exclusively through Immunovia, Inc.
For more information see: www.immunoviainc.com.
Immunovia's shares (IMMNOV) are listed on Nasdaq Stockholm. For
more information, please
This information was brought to you by
The following files are available for download:
SOURCE Immunovia AB